Praluent logo

Prescribing Information(GB)

Prescribing Information(NI)

Second MI
6 weeks ago

Age: 55 years
LDL-C: 3.6 mmol/L 
Polyvascular disease  (CAD & PAD) 
Smoker

First MI
12 months ago

Age: 63 years
LDL-C: 5.0 mmol/L
Familial hypercholesterolaemia 
Non-smoker

First MI
6 months ago

Age: 63 years
LDL-C: 4.1 mmol/L
No additional comorbidities or family history of heart disease
Non-smoker

Any ACS means the patient is at very high CV risk, regardless of comorbidities1

    1. March F, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias; lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188.
SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team

MAT-XU-2201545 (v3.0)
Date of Preparation: February 2023

MAT-XU-2204602 (v2.0)  
Date of Preparation: March 2023